Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Osteoarthritis cartilage histopathology: grading and staging.
- K. Pritzker, S. Gay, +5 authors W. B. van den Berg
- Osteoarthritis and cartilage
- 31 January 2006
An OA cartilage pathology assessment system based on six grades, which reflect depth of the lesion and four stages reflecting extent of OA over the joint surface was developed and appears consistent and simple to apply. Expand
Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders.
- S. Piera-Velázquez, Zhaodong Li, S. Jimenez
- Biology, Medicine
- The American journal of pathology
- 1 September 2011
EndoMT may be an important mechanism in the pathogenesis of pulmonary, cardiac, and kidney fibrosis, and may represent a novel therapeutic target for fibrotic disorders. Expand
Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs
- E. Londin, Phillipe Loher, +35 authors I. Rigoutsos
- Medicine, Biology
- Proceedings of the National Academy of Sciences
- 23 February 2015
The findings suggest that the repertoire of human miRNAs is far more extensive than currently represented by public repositories and that there is a significant number of lineage- and/or tissue-specific mi RNAs that are uncharacterized. Expand
A disease severity scale for systemic sclerosis: development and testing.
This preliminary severity scale will be useful for assessing disease severity status in individual patients both at one point in time and longitudinally and serve as a framework for developing a scleroderma disease activity index. Expand
NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis.
Promising strategies such as improved antisense DNA therapy and RNA interference have been examined with encouraging results, but further research will be needed before NF-kappaB-aimed strategies become an effective therapy for joint diseases, such as OA and RA. Expand
Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis
The Raynaud phenomenon, swelling of the extremities, and diffuse arthralgias often precede the onset of skin tightness and induration, and a better understanding of the pathogenesis of this incurable disorder will help to design effective therapies in the future. Expand
Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature.
- F. Mendoza, C. Artlett, N. Sandorfi, K. Latinis, S. Piera-Velázquez, S. Jimenez
- Seminars in arthritis and rheumatism
- 1 February 2006
NFD is a severe and usually progressive systemic fibrotic disease affecting the dermis, subcutaneous fascia, and striated muscles and it also appears that the disease can cause fibrosis of lungs, myocardium, and other organs. Expand
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis
Promising strategies such as improved antisense DNA therapy and RNA interference have been examined with encouraging results, but further research will be needed before NF-κB-aimed strategies become an effective therapy for joint diseases, such as OA and RA. Expand
A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation.
It is demonstrated that the Tsk chromosome harbors a 30- to 40-kb genomic duplication within the FBN1 gene that results in a larger than normal in-frame Fbn1 transcript, which provides hypotheses to explain some of the phenotypic characteristics of Tskl + mice and the lethality of T Sk embryos. Expand
Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro.
The results suggest that the family of Sp1 transcription factors play a role in physiological and pathological modulation of connective tissue accumulation and Alterations in the relative amounts or DNA-binding activities of these transcription factors in a cell- or signal-specific manner may contribute to the control of transcription from the COL1A1 promoter. Expand